Ocugen, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Ocugen, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 77% in 3 years; of every extra $100 of sales, $985 became extra profit. Higher than 97% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-11.5×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 53% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
$985Sales grew 77% in 3 years; of every extra $100 of sales, $985 became extra profit.
Higher than 97% of Healthcare companies in United States.
Asset Productivity Ratio
+77% / -60%In 3 years sales changed by +77% while total assets changed by -60%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-45.6×Operating cash was negative last year, while some debt falls due within a year.
Lower than 71% of Healthcare companies in United States.
Cash Cushion Ratio
−5%Debt, after subtracting cash, equals 5% of its market value (net debt).
Lower than 75% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Ocugen, Inc. made a loss over the last year. Ocugen, Inc. owes $1.13 for every $1 it owns. Ocugen, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossOcugen, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-16.18Ocugen, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$268 MThe total market value of all of Ocugen, Inc.'s shares at today's price (share price × number of shares), smaller than 53% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
NegativeOcugen, Inc.'s net worth is negative ($17 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
1.13×Ocugen, Inc. owes $1.13 for every $1 it owns, so it owes more than it owns, higher than 90% of Healthcare companies in United States.
Dividend yield
NoneOcugen, Inc. does not currently pay a dividend.
Revenue growth
+9%Revenue rose 9% in the year to Dec 2025, and grew 21% a year on average over 3 years.
Profit growth
LossOcugen, Inc. made a loss in each of the last two years.
Profit margin
-1537.4%Ocugen, Inc. lost $1537 for every $100 of revenue.
Interest cover
Not coveredOcugen, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtOcugen, Inc. had $15 M more debt than cash (net debt) at Dec 2025.
Questions
How much does Ocugen, Inc. owe compared with what it owns?
Ocugen, Inc. owes $1.13 for every $1 it owns, so it owes more than it owns, higher than 90% of Healthcare companies in United States.
Does Ocugen, Inc. pay a dividend?
No. Ocugen, Inc. does not currently pay a dividend.
Is Ocugen, Inc.'s revenue growing?
Revenue rose 9% in the year to Dec 2025, and grew 21% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.